The SLIM-1 trial approval is an early-stage de-risking event for VANI's GLP-1 implant pipeline, but with only 20 patients and a four-week duration, meaningful efficacy data is months away. Traders should watch for SLIM-1 initiation timing and any early safety/PK readouts. The equity plan increase is routine post-approval — no immediate dilution event.
Price Chart
Executive Summary
Vivani Medical filed an 8-K reporting shareholder approval of an amended equity incentive plan (increasing authorized shares by 11M to 21,033,333) and announcing regulatory approval in Australia to initiate a Phase 1 trial of its NPM-139 semaglutide implant for obesity (SLIM-1). The trial approval is a modest clinical catalyst for this clinical-stage biotech, while the equity plan increase enables future employee incentives without immediate dilution.
Key Facts
- Shareholders approved the Amended and Restated 2022 Omnibus Incentive Plan on June 24, 2026, increasing the share reserve by 11,000,000 shares to a total of 21,033,333 shares.
- All six director nominees were elected with overwhelming support (votes for ranging from 47,435,960 to 47,888,337).
- Vivani received HREC (Bellberry) approval in Australia to initiate SLIM-1, a Phase 1 open-label, randomized, active comparator-controlled trial of NPM-139 (semaglutide implant) vs. Wegovy (0.25 mg/week) over four weeks in 20 obese/overweight subjects.
- CEO stated SLIM-1 initiation is expected in mid-2026, with preparation underway for a subsequent dose-ranging efficacy trial (SLIM-2) pending SLIM-1 results.
- The company's prior Phase 1 trial of NPM-119 (exenatide implant) was successfully conducted in Australia in 2025.
Financial Impact
No financial figures disclosed. The sole catalyst is regulatory clearance to initiate a small Phase 1 trial — no revenue, EPS, or cash runway data provided.
Risk Factors
- Phase 1 trial may fail to show adequate safety/tolerability or PK profile.
- Competition in the GLP-1 implant space from larger players.
- No disclosed financial runway or cash position — small-cap biotech financing risk persists.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001753926-26-001109 |
| Exhibit: ex991_2.htm | 0001753926-26-001109 |
| Document: vani-20260624.htm | 0001753926-26-001109 |
| Document: 0001753926-26-001109-index-headers.html | 0001753926-26-001109 |
| Document: 0001753926-26-001109-index.html | 0001753926-26-001109 |
| Document: 0001753926-26-001109.txt | 0001753926-26-001109 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 424B5 | $1.25 $1.13 | ▲ +9.60% | ▲ +9.57% | $1.16 (+7.20%) |
Aug 17, 2026 10w ago | 8-K | $1.35 $1.23 | ▼ −8.89% | ▼ −6.91% | $1.16 (−14.07%) |
Jul 16, 2026 14w ago | 8-K | $1.35 $1.34 | ▼ −0.74% | ▼ −4.36% | $1.16 (−14.07%) |
Jul 7, 2026 16w ago | 8-K | $1.35 $1.33 | ▼ −1.48% | ▼ −2.81% | $1.16 (−14.07%) |
Jul 2, 2026 16w ago | Press Release | $1.26 $1.30 | ▲ +3.17% | ▲ +3.59% | $1.16 (−7.94%) |
Jun 30, 2026 17w ago | 8-K | $1.24 $1.30 | ▲ +4.84% | ▲ +5.87% | $1.16 (−6.45%) |
Jun 4, 2026 20w ago | 8-K | $1.28 $1.26 | ▼ −1.56% | ▼ −0.19% | $1.16 (−9.38%) |
Mar 26, 2026 30w ago | Press Release | $1.02 $1.39 | ▲ +36.27% | ▲ +23.53% | $1.16 (+13.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers